GKIM
VRTX icon

GW&K Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GW&K Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
209
+23
+12% +$10.2K ﹤0.01% 472
2026
Q1 		$83K Buy
186
+35
+23% +$16.3K ﹤0.01% 484
2025
Q4 		$68K Buy
151
+8
+6% +$3.45K ﹤0.01% 507
2025
Q3 		$56K Sell
143
-18
-11% -$7.52K ﹤0.01% 515
2025
Q2 		$72K Buy
161
+18
+13% +$8.29K ﹤0.01% 462
2025
Q1 		$69K Buy
143
+11
+8% +$5.13K ﹤0.01% 440
2024
Q4 		$53K Sell
132
-1
-0.8% -$464 ﹤0.01% 466
2024
Q3 		$62K Buy
133
+32
+32% +$15.4K ﹤0.01% 442
2024
Q2 		$47K Buy
101
+18
+22% +$7.81K ﹤0.01% 452
2024
Q1 		$35K Sell
83
-13
-14% -$5.5K ﹤0.01% 462
2023
Q4 		$39K Buy
96
+3
+3% +$1.11K ﹤0.01% 433
2023
Q3 		$32K Buy
93
+4
+4% +$1.4K ﹤0.01% 434
2023
Q2 		$31K Buy
+89
New +$30K ﹤0.01% 427
2022
Q3 		– Sell
-30
Closed -$8K – 808
2022
Q2 		$8K Buy
30
+12
+67% +$3.21K ﹤0.01% 505
2022
Q1 		$5K Buy
+18
New +$4.27K ﹤0.01% 556

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GW&K Investment Management's VRTX Position: Q2 2026 in Review

GW&K Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $10.2K and bringing the position to 209 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #472.

GW&K Investment Management first reported a position in VRTX in Q1 2022 and has held it in 15 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • GW&K Investment Management held 209 shares of Vertex Pharmaceuticals worth $104K as of Q2 2026.
  • GW&K Investment Management bought 23 Vertex Pharmaceuticals shares in Q2 2026, an estimated $10.2K.
  • Vertex Pharmaceuticals made up ﹤0.01% of GW&K Investment Management's portfolio in Q2 2026, its #472 holding.
  • GW&K Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.